Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activities of coproporphyrinogen oxidase, protoporphyrinogen oxidase and
ferrochelatase
have been assayed in human liver biopsies using recently developed highly sensitive specific enzyme assays. The specific activities (nmol/min/mg protein) in controls were 0.010 +/- 0.003 (mean +/- S.D., n = 11), 0.18 +/- 0.07 (n = 9) and 0.062 +/- 0.022 (n = 8), respectively. The total activities (mumol/min/liver) were determined, using ultrasound to determine liver volumes, and were 2.6 +/- 0.6 (n = 5), 36.6 +/- 13.9 (n = 6) and 14.2 +/- 5.4 (n = 3), respectively. Both specific and total enzyme activities in alcoholics with
fatty liver
were not significantly different from normal controls. Decreased protoporphyrinogen oxidase activity (0.08 nmol/min/mg protein or 20.2 mumol/min/liver) was found in two patients with variegate porphyria. In a patient with erythrohepatic protoporphyria a reduction of the
ferrochelatase
activity (0.01 nmol/min/mg protein) was demonstrated.
...
PMID:Coproporphyrinogen oxidase, protoporphyrinogen oxidase and ferrochelatase activities in human liver biopsies with special reference to alcoholic liver disease. 292 8